Cerevel Therapeutics Statistics
Share Statistics
Cerevel Therapeutics has 182.2M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 182.2M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 94.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,782,602 |
| FTD / Avg. Volume | 232.56% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -15.87 and the forward
PE ratio is null.
Cerevel Therapeutics's PEG ratio is
-1.05.
| PE Ratio | -15.87 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 10.2 |
| P/FCF Ratio | -19.85 |
| PEG Ratio | -1.05 |
Financial Ratio HistoryEnterprise Valuation
Cerevel Therapeutics has an Enterprise Value (EV) of 6.36B.
| EV / Sales | 0 |
| EV / EBITDA | -14.4 |
| EV / EBIT | -18.58 |
| EV / FCF | -18.38 |
Financial Position
The company has a current ratio of 10.92,
with a Debt / Equity ratio of 0.55.
| Current Ratio | 10.92 |
| Quick Ratio | 10.92 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | -1.09 |
| Debt / FCF | -1.39 |
| Interest Coverage | -42.33 |
Financial Efficiency
Return on Equity is -64.24% and Return on Invested Capital is -42.96%.
| Return on Equity | -64.24% |
| Return on Assets | -34.81% |
| Return on Invested Capital | -42.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,219,273.24 |
| Employee Count | 355 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 503K |
| Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by 7.3% in the
last 52 weeks. The beta is 1.41, so Cerevel Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.41 |
| 52-Week Price Change | 7.3% |
| 50-Day Moving Average | 41.66 |
| 200-Day Moving Average | 38.78 |
| Relative Strength Index (RSI) | 72.45 |
| Average Volume (20 Days) | 2,056,487 |
Income Statement
| Revenue | n/a |
| Gross Profit | -5.63M |
| Operating Income | -447.26M |
| Net Income | -432.84M |
| EBITDA | -441.64M |
| EBIT | -421.77M |
| Earnings Per Share (EPS) | -2.67 |
Full Income StatementBalance Sheet
The company has 990.97M in cash and 480.78M in
debt, giving a net cash position of 510.19M.
| Cash & Cash Equivalents | 990.97M |
| Total Debt | 480.78M |
| Net Cash | 510.19M |
| Retained Earnings | -1.4B |
| Total Assets | 1.13B |
| Working Capital | 775.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -342.3M
and capital expenditures -3.81M, giving a free cash flow of -346.11M.
| Operating Cash Flow | -342.3M |
| Capital Expenditures | -3.81M |
| Free Cash Flow | -346.11M |
| FCF Per Share | -2.14 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
